

PRIOR AUTHORIZATION REQUEST FORM Neuromyelitis Optica Spectrum Disorder (NMOSD)

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: University of Utah Health Employees: 855-856-5690, Individual & Family Plans: 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements. Date: Member Name: ID#: DOB: Gender: Physician: Office Phone: Office Contact: Office Fax: Height/Weight: **HCPCS Code:** Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested: ☐ Enspryng * (satralizumab), ☐ Ruxience * (rituximab-pvvr), ☐ Soliris* (eculizumb), ☐ Uplizna™ (inebilizumab-cdon) Dosing/Frequency: If the request is for reauthorization, proceed to reauthorization section. **Comments/Notes** Questions Yes No 1. Is the request made by, or in consultation with, a specialist in П \Box the treatment of neuromyelitis optica spectrum disorder (NMOSD)? 2. Does the member have a confirmed diagnosis of NMOSD with Please provide documentation positive AQP-4 antibodies and at least one core clinical characteristic such as: optic neuritis, acute myelitis, area postrema syndrome, acute brainstem syndrome, symptomatic narcolepsy, acute diencephalic clinical syndrome, or symptomatic cerebral syndrome with brain lesions? 3. Is an Expanded Disability Status Scare (EDSS) score equal to 8 or Please provide documentation less? 4. Has the member had at least 1 relapse that required rescue Please provide documentation П П therapy in the last 12 months or 2 or more relapses that required rescue therapy in the last 24 months? 5. Has the member had an adequate trial and failure of any of the Please provide documentation medications listed in this policy? **REAUTHORIZATION** 1. Is the request for reauthorization of therapy? 2. Does documentation show a clinically significant response to Please provide documentation П therapy demonstrated by one of the following:

 Decrease in relapse rate 				
 Improvement of symptoms or stabilization of symptoms 				
associated with relapse				
 Improvement in EDSS score 				
What medications and/or treatment modalities have been tried in the past for this condition? Please document				
name of treatment, reason for failure, treatment dates, etc.				
Additional information:				
Physician Signature:				

** Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

Policy: PHARM-M027

Origination Date: 07/09/2020 Reviewed/Revised Date: 05/18/2022 Next Review Date: 05/18/2023 Current Effective Date: 06/01/2022

Confidentiality Notice